Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus

Kelly L. Gorres,*a Derek Daigle,*b Sudharshan Mohanram,a Grace E. McInerney,a Danielle E. Lyons,b George Miller*a,c,d

Department of Molecular Biophysics and Biochemistry,a Department of Microbiology,b Department of Pediatrics,c and Department of Epidemiology and Public Health,d Yale University School of Medicine, New Haven, Connecticut, USA

* Present address: Kelly L. Gorres, University of Wisconsin La Crosse, La Crosse, Wisconsin, USA.

ABSTRACT Reactivation of Epstein-Barr virus (EBV) from latency into the lytic phase of its life cycle allows the virus to spread among cells and between hosts. Valproic acid (VPA) inhibits initiation of the lytic cycle in EBV-infected B lymphoma cells. While VPA blocks viral lytic gene expression, it induces expression of many cellular genes, because it is a histone deacetylase (HDAC) inhibitor. Here we show, using derivatives of VPA, that blockade of EBV reactivation is separable from HDAC inhibition. Valpromide (VPM), an amide derivative of valproic acid that is not an HDAC inhibitor, prevented initiation of the EBV lytic cycle. VPM did not alter expression of several other cellular immediate-early genes, including STAT3, when BZLF1 was exogenously expressed. Unlike VPA, VPM did not activate expression of these cellular immediate-early genes but decreased their level of expression when induced by butyrate, an HDAC inhibitor. VPM did not alter expression of several other cellular immediate-early genes, including STAT3, which were induced by the HDAC inhibitors in cells refractory to lytic induction. Therefore, VPM selectively inhibits both viral and cellular gene expression. VPA and VPM represent a new class of antiviral agents. The mechanism by which VPA and VPM block EBV reactivation may be related to their anticonvulsant activity.

IMPORTANCE Epstein-Barr virus (EBV), a human tumor virus, establishes a life-long latent infection. Reactivation of EBV into the lytic phase of its life cycle allows the virus to spread. Previously, we showed that EBV reactivation was blocked by valproic acid (VPA), an inhibitor of cellular histone deacetylases (HDACs). VPA alters the expression of thousands of cellular genes. In this study, we demonstrate that valpromide (VPM), an amide derivative of valproic acid that is not an HDAC inhibitor, prevented initiation of the EBV lytic cycle. VPA induced lytic reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV), but VPM did not. Unlike VPA, VPM did not activate cellular immediate-early gene expression. VPM is a new type of antiviral agent. VPM will be useful in probing the mechanism of EBV lytic reactivation and may have therapeutic application.

Received 21 January 2016 Accepted 26 January 2016 Published 1 March 2016

Citation Gorres KL, Daigle D, Mohanram S, McInerney GE, Lyons DE, Miller G. 2016. Valpromide inhibits lytic cycle reactivation of Epstein-Barr virus. mBio 7(2):e00113-16. doi: 10.1128/mBio.00113-16.

Editor Diane E. Griffin, Johns Hopkins Bloomberg School of Public Health

Copyright © 2016 Gorres et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to George Miller, george.miller@yale.edu.

This article is a direct contribution from a Fellow of the American Academy of Microbiology. External solicited reviewers: Nancy Raab-Traub, University of North Carolina; Shannon C. Kenney, University of Wisconsin-Madison.

E pstein-Barr virus (EBV), a human gammaherpesvirus, causes infectious mononucleosis and other lymphoproliferative diseases. EBV is intimately associated with lymphomas and with carcinomas of the stomach and nasopharynx. Like all herpesviruses, EBV establishes a latent infection that is periodically reactivated into the productive lytic cycle. While the physiologic mechanisms by which the EBV lytic cycle is reactivated in immunocompetent people are not known, lytic reactivation can be triggered in cultured cells by various inducing agents, including the short-chain fatty acid butyrate (1). However, medium-chain fatty acids, including valproic acid (VPA), block reactivation of the EBV lytic cycle caused by inducing agents in Burkitt lymphoma cells (2).

VPA and butyrate are both histone deacetylase (HDAC) inhibitors. One potential mechanism of action to account for the differential effects of butyrate and VPA on EBV reactivation may lie in the specific modifications of chromatin that are produced by the two agents. However, a number of experiments have provided evidence that histone modification and EBV lytic reactivation do not always correlate. (i) VPA and butyrate both inhibit class I and IIa HDACs (3). (ii) Markers characteristic of open chromatin, namely, hyperacetylation of histone H3 at lysine 9 (K9) and K14 and dimethylation of H3 at K4, are globally induced in EBV-positive HH514-16 cells treated with VPA, yet VPA does not induce the viral lytic cycle in these cells (4). (iii) Markers of open chromatin, consisting of hyperacetylation of histones H3 (K9 and K14) and H4 (K5, K8, K12, and K16), and phosphorylation of serine 10 on histone H3 were induced by butyrate in Raji cells, yet the EBV lytic cycle was not activated. (iv) In HH514-16 cells treated with butyrate, hyperacetylation of histone H3 was detected both in the subpopulation of cells that entered the lytic cycle and in the cells that remained refractory to viral reactivation (5). (v) Investigations of histone modifications, specifically at promoters of viral lytic genes, revealed no differences in histone H3 hyperacetylation at the BZFL1 promoter in HH514-16 cells treated with...
butyrate or VPA. (vi) Furthermore, the HDAC inhibitory activity of a panel of structurally related short-chain fatty acids did not correlate with activation or blockage of EBV reactivation (2). Therefore, a mechanism other than HDAC inhibition must contribute to the blockade of EBV lytic reactivation by VPA.

Another possibility that could account for the differential effects of VPA versus butyrate on EBV reactivation is selective alteration of expression of cellular genes. Cellular gene expression is required before expression of viral transactivator genes (6). Butyrate may specifically activate expression of a gene required for EBV lytic activation, while VPA may activate a repressor. However, since butyrate and VPA are HDAC inhibitors, they each change the expression of thousands of genes. This makes the identification and characterization of specific genes required for either activating or repressing EBV lytic reactivation difficult. In fact, in cells treated with VPA or butyrate, the changes in cellular gene expression are largely overlapping (7).

In this report, we sought to determine whether the ability of VPA to block EBV reactivation is dependent on its property of inhibiting HDACs. Therefore, we examined valpromide (VPM), an analog in which the carboxylic acid of VPA is replaced with an amide (Fig. 1). Pertinent to this study, VPM is not known to be an HDAC inhibitor (8). To compare the effects of VPA and VPM on the EBV lytic cycle, we treated EBV-positive Burkitt lymphoma cells (HH514-16) for 24 and 48 h with VPA or VPM (10 mM) in the presence or absence of butyrate (3 mM). VPM treatment did not alter cell viability, as determined by trypan blue staining. Cells treated with VPM did not exhibit increased levels of acetylated histone H3 (AcH3) (Fig. 2A), while those treated with butyrate and VPA, known HDAC inhibitors, manifest, as expected, increased histone H3 acetylation. Increased histone H3 acetylation was still observed in cells treated with butyrate combined with VPM, demonstrating that VPM does not block the HDAC-inhibitory property of butyrate.

We measured EBV reactivation in HH514-16 BL cells treated with butyrate, VPA, or VPM. The expression of the viral lytic transactivator protein Zebra was the marker of lytic reactivation. Zebra was detected in cells treated with butyrate, a known inducer of the EBV lytic cycle in this cell background, but not in cells treated with VPA or VPM (Fig. 2A). As shown previously, VPA blocked expression of Zebra by butyrate (7). VPA also inhibited Zebra expression induced by butyrate. In addition to blocking expression of Zebra protein, VPM blocked expression of BZLF1 mRNA (data not shown) and BRLF1 mRNA (Fig. 2B). VPM also blocked EBV reactivation induced by tetradecanoyl phorbol acetate (TPA), a protein kinase C agonist, in Raji cells, as indicated by inhibition of expression of viral immediate-early genes BZLF1 and BRLF1.

### RESULTS

**Valpromide, which is not an HDAC inhibitor, blocks EBV lytic reactivation in Burkitt lymphoma cells.** VPA, an HDAC inhibitor, blocks lytic reactivation of EBV by all known inducing agents, including other HDAC inhibitors, in Burkitt lymphoma (BL) cells (7). To determine whether the blockade of EBV reactivation by VPA correlated with its HDAC inhibitory activity, we studied VPM (2-propyl-pentanamide), the carboximide derivative of VPA (Fig. 1). Pertinent to this study, VPM is not known to be an HDAC inhibitor (8). To compare the effects of VPA and VPM on the EBV lytic cycle, we treated EBV-positive Burkitt lymphoma cells (HH514-16) for 24 and 48 h with VPA or VPM (10 mM) in the presence or absence of butyrate (3 mM). VPM treatment did not alter cell viability, as determined by trypan blue staining. Cells treated with VPM did not exhibit increased levels of acetylated histone H3 (AcH3) (Fig. 2A), while those treated with butyrate and VPA, known HDAC inhibitors, manifest, as expected, increased acetylation of histone H3. Increased histone H3 acetylation was still observed in cells treated with butyrate combined with VPM, demonstrating that VPM does not block the HDAC-inhibitory property of butyrate.

We measured EBV reactivation in HH514-16 BL cells treated with butyrate, VPA, or VPM. The expression of the viral lytic transactivator protein Zebra was the marker of lytic reactivation. Zebra was detected in cells treated with butyrate, a known inducer of the EBV lytic cycle in this cell background, but not in cells treated with VPA or VPM (Fig. 2A). As shown previously, VPA blocked expression of Zebra by butyrate (7). VPA also inhibited Zebra expression induced by butyrate. In addition to blocking expression of Zebra protein, VPM blocked expression of BZLF1 mRNA (data not shown) and BRLF1 mRNA (Fig. 2B). VPM also blocked EBV reactivation induced by tetradecanoyl phorbol acetate (TPA), a protein kinase C agonist, in Raji cells, as indicated by inhibition of expression of viral immediate-early genes BZLF1 and BRLF1.

**FIG 1** Structures of fatty acids and their amide derivatives studied for effects on the EBV lytic cycle. (Left column) Butyrate, isovalerate (3-methylbutyrate), VPA (2-propylpentanoate), and 4ynVPA (2-propyl-4-pentyanoate). (Right column) Butyramide, isovaleramide, and VPM. HDACi, HDAC inhibitor.
This experiment showed that VPM inhibits the action of another inducing agent that works by a mechanism distinct from that of butyrate in a separate Burkitt lymphoma cell line (Fig. 2C).

**Effects of other derivatives of fatty acids on EBV lytic reactivation.** We investigated the effects on lytic reactivation of another derivative of VPA, 2-propyl-4-pentynoic acid (4ynVPA; ABS205; Abcam) (Fig. 1). 4ynVPA is a known HDAC inhibitor (9), like VPA. In HH514-16 Burkitt lymphoma cells treated with 4ynVPA, levels of AcH3 were increased, although not to the extent following treatment with butyrate and VPA (Fig. 3A). Like VPA, 4ynVPA (10 mM) did not induce expression of BZLF1 mRNA (Fig. 4B) or protein (Fig. 3A). However, unlike VPA, 4ynVPA did not block induction of BZFL1 by butyrate. These results provide additional evidence that inhibition of HDACs is not sufficient for either promoting or inhibiting EBV lytic reactivation.

Because VPM, the amide derivative of VPA, was an effective inhibitor of EBV lytic reactivation, we investigated the properties of amide derivatives of butyrate and isovalerate, two fatty acid HDAC inhibitors that activate the EBV lytic cycle (2) (Fig. 4). Treatment of HH514-16 Burkitt lymphoma cells with the amide derivatives, butyramide and isovaleramide (Fig. 1), did not cause an increase in acetylated histone H3 (Fig. 4A). Neither butyramide nor isovaleramide induced expression of ZEBRA protein (Fig. 4A) or BRLF1 mRNA expression (Fig. 4B). Unlike VPM, neither butyramide nor isovaleramide blocked reactivation of the EBV lytic cycle, as measured by expression of Zebra protein or BRLF1 mRNA. This result showed that simply converting a fatty acid to the corresponding amide is not sufficient to create an EBV lytic cycle inhibitor. VPM is a novel inhibitor of EBV lytic reactivation. The structure of the carbon chain in VPM is crucial for its function in inhibiting EBV reactivation.

**VPM blocks butyrate-induced expression of the BZLF1 promoter.** VPA and VPM block accumulation of BZLF1 mRNA when BL cells are treated with an inducing agent (Fig. 2B). This activity could reflect effects of VPA and VPM on elongation or stability of BZLF1 mRNA or initiation of mRNA transcription. We showed previously that butyrate upregulates expression of a luciferase (luc) reporter driven by the BZLF1 promoter (Zp) and that VPA blocks Zp-luc expression by butyrate. Here, we show that VPM, like VPA, does not induce Zp-luc expression and blocks stimulation of this reporter by butyrate (Fig. 5). We tested a number of mutations in the Zp reporter in our attempt to map the locus of
the inhibitory action of VPM. To test whether VPM blocks autostimulation of Zp, we created inactivating mutations in the ZIIIA/ZIIIB sites within Zp that are known to mediate autostimulation (10). The inhibitory effect of VPM was maintained on Zp reporters with inactivating mutations in the ZIIIA/ZIIIB autostimulatory sites (Fig. 5B). The inhibitory effect of VPM was also evident on Zp-luc reporters with inactivating mutations of previously mapped repressive elements, ZV/ZV′ and ZIIR (11, 12). Although the ZV/ZV′/ZIIR mutations in Zp-luc were accompanied by an 8-fold increase in Zp expression in response to butyrate (Fig. 5C), VPM still repressed the activity of butyrate. We conclude that neither VPA nor VPM blocks Zp expression via a repressive mechanism that is mediated by the ZV/ZV′ or ZIIR sites.

**VPA and VPM block EBV late protein expression in the presence of Zebra protein.** To determine whether or not VPA and VPM inhibit any other phase of the lytic cycle kinetically downstream of BZLF1 expression, we transfected HH514-16 BL cells with a plasmid that constitutively expressed BZLF1 and then treated the cells with butyrate, VPA, or VPM or left them untreated. Zebra protein was expressed from the plasmid in cells treated with VPM at a level similar to that in untreated cells (Fig. 6). Zebra expression was increased in the presence of the HDAC inhibitors butyrate or VPA, due to enhanced expression from the cytomegalovirus (CMV) IE promoter in the plasmid (13). The levels of expression of the viral transactivator Rta (BRLF1 gene) and early EA-D (BMRF1) proteins mirrored the expression pattern of Zebra. The levels of Rta and EA-D were enhanced in the presence of butyrate and VPA; their levels were similar in cells treated with VPM or untreated after transfection with BZLF1. These results showed that neither VPA nor VPM blocks the function of Zebra in activating early protein expression. However, late protein expression of small capsid protein FR3 (BFRF3) was inhibited by VPA and VPM, but not by butyrate. In these cells in which FR3 protein was not detected, lytic EBV DNA

![FIG 3](image-url) The VPA analog 4ynVPA, an HDAC inhibitor, does not activate or block EBV lytic reactivation. (A) HH514-16 EBV⁺ Burkitt lymphoma cells were treated with 4ynVPA (3 mM) in the presence or absence of butyrate (NaB; 3 mM) for 24 h. Lytic induction was measured by immunoblotting with anti-Zebra antibody. Protein levels, normalized to β-actin levels, were expressed relative to the amount in the untreated control cells. (B) HH514-16 EBV⁺ Burkitt lymphoma cells were treated with 4ynVPA (10 mM) in the presence or absence of butyrate (3 mM) for 24 h. Lytic induction was determined based on the relative expression of BZLF1, measured by RT-qPCR, in triplicates of extracted RNA. Data are representative of results with biological duplicates. n.s., not statistically significant (P > 0.05).

![FIG 4](image-url) Amide derivatives of butyrate and isovalerate do not activate or block the EBV lytic cycle. HH514-16 EBV⁺ Burkitt lymphoma cells were treated with butyramide (10 mM) or isovaleramide (10 mM) in the presence or absence of butyrate (3 mM) for 24 h. (A) Lytic induction and HDAC inhibition were measured by immunoblotting, as described for Fig. 3. (B) Lytic induction was determined based on the relative expression of BRLF1, measured by RT-qPCR, in triplicate. Data are representative of results for biological triplicates. n.s., not statistically significant (P > 0.05).
replication was detected by quantitative PCR (qPCR). Therefore, VPA and VPM block the EBV lytic cycle at two steps: very early gene expression (BZLF1) and late protein (FR3) expression.

Comparison of effects of VPA and VPM on cellular gene expression. In previous work, we showed that expression of cellular immediate-early genes, including FOS and EGR1, is temporally upstream of expression of the viral BZLF1 and BRLF1 genes in two BL cell lines, Akata and HH514-16 cells, treated with lytic cycle-inducing agents appropriate for each cell line, namely, anti-Ig for Akata and butyrate or trichostatin A for HH514-16 (7, 14). We compared the effects of VPA and VPM on expression of cellular immediate-early genes EGR1 and FOS in HH514-16 cells. VPA induced expression of EGR1 and FOS, though to a lesser extent than butyrate, in HH514-16 cells treated for 6 h. VPA did not inhibit the induction of these two cellular genes by butyrate. In contrast, VPM did not promote expression of EGR1 and FOS and VPM inhibited their induction by butyrate (Fig. 7A and B). Since VPM is not an HDAC inhibitor, its failure to promote expression of EGR1 and FOS was not unexpected. However, the inhibitory effect of VPM on EGR1 and FOS expression showed that VPM and VPA differ in their modulating effects on cellular gene expression.

We expanded the comparison of VPA and VPM by examining their effects on four cellular genes whose expression is enriched in HH514-16 BL cells that are refractory to lytic induction (5). The two HDAC inhibitors, butyrate and VPA, induced expression of FRMD6, SEPP1, and STAT3 at 6 h. VPM did not enhance the expression of these genes compared to untreated control cells (Fig. 7C to E). In addition, VPM did not inhibit induction of FRMD6, SEPP1, or STAT3 by butyrate. The two HDAC inhibitors butyrate and VPA decreased expression of the MIR17HG locus; VPM did not alter expression of this locus (Fig. 7F). Expression of MIR17HG was still decreased by butyrate, even in the presence of VPM. The effects of the HDAC inhibitors butyrate and VPA on the expression of FRMD6, SEPP1, STAT3, and MIR17HG differed from the effects of the non-HDAC inhibitor VPM. Since VPM did not impact the alterations in gene expression induced by butyrate, we conclude that VPM did not block EBV lytic reactivation by facilitating expression of these four genes that are characteristic of the refractory state. While VPM inhibited expression of two immediate-early cellular genes but did not alter expression of four genes upregulated in refractory cells, VPM is not a global inhibitor but is a selective inhibitor of cellular gene expression.

Valpromide does not induce or block the KSHV lytic cycle. Although VPA blocks lytic reactivation of EBV in Burkitt lymphoma cells, VPA activates the lytic cycle of KSHV, another human gammaherpesvirus in primary effusion lymphoma (PEL) cells (15). Our earlier work showed that, unlike EBV, KSHV lytic reactivation correlates with HDAC inhibition by short-chain fatty acids (2). We postulated that VPM, which is not an HDAC inhib-
itor, would not activate KSHV. In KSHV-positive HH-B2 PEL cells treated with VPM, expression of the viral transactivator ORF50 gene was not induced (Fig. 8). In addition, the ORF50 gene was still expressed in cells treated with VPM plus butyrate. Therefore, VPM neither activates nor blocks KSHV lytic reactivation. VPM is not a general inhibitor of viral lytic reactivation.

**DISCUSSION**

**Structure-function relationship among inhibitors of EBV lytic reactivation that are antiepileptic agents.** VPA is widely used to treat epilepsy, mood disorders, and migraine headaches. Despite its widespread use, VPA can cause serious side effects, including liver toxicity and teratogenicity. To identify antiepileptic drugs with reduced side effects, derivatives of VPA have been synthesized. By utilizing these derivatives of VPA, a previously identified inhibitor of EBV reactivation, we are able to provide additional insights into structural features of fatty acids that are important for inhibition of the lytic cycle of EBV. 4ynVPA (Fig. 1), containing a triple bond in one of the carbon side chains of VPA, retains some anticonvulsant activity but is less effective than VPA (16). The S isomer of 4ynVPA, like VPA, is an HDAC inhibitor (9) but is more teratogenic than VPA (17). Teratogenicity correlates with HDAC inhibition (18). In our studies, a racemic mixture of 4ynVPA behaved as an HDAC inhibitor but neither activated, nor blocked, EBV lytic reactivation (Fig. 3). This result confirmed our previous conclusions that neither the stimulatory nor inhibitory effects of fatty acids on EBV reactivation correlate with HDAC inhibition (2). The anticonvulsant properties of VPA are maintained in analogs that are not HDAC inhibitors (18, 19). Converting the carboxylic acid in VPA to an amide creates VPM (Fig. 1). VPM, like VPA, is an antiepileptic drug. However, VPM is neither a teratogen (20) nor an HDAC inhibitor (21). Here, we report that VPM is a novel inhibitor of EBV reactivation (Fig. 2).

We hypothesize that the effects of VPA and VPM in blocking EBV reactivation are related to their properties as anticonvulsants. The precise mechanism of action of VPA as an antiepileptic drug is not known. A number of activities have been postulated, such as effects on ion channels, GABAergic and glutamatergic neurotransmitter activities, and cell signaling kinases, including inositol-dependent signaling (22).

**VPM blocks upregulation of cellular immediate-early genes by butyrate.** The EBV lytic cycle can be triggered by many different molecules with disparate effects on the host cell, including protein kinase C agonists, cross-linking of the B-cell receptor by anti-immunoglobulin, the DNA demethyltransferase inhibitor azacytidine, and many different classes of HDAC inhibitors, including butyrate, trichostatin A, and suberoylanilide hydroxamic acid (7). Cells react to these stimuli by altering expression of cellular IE genes that characteristically respond rapidly to extracellular signals such as hormones or stress. Activation of expression of the EBV transactivator genes, BZLF1 and BRLF, occurs after expression of cellular immediate-early genes, including EGR1 and FOS (14). Evidence suggests that EGR1, FOS, and other cellular IE genes play an essential role in EBV lytic reactivation. EGR1 acti-
vates the promoter of the EBV BRLF1 gene (23). Transfection of Akata cells with plasmids expressing EGR1 and other cellular immediate-early genes, namely, EGR2, NR4A1, and NR4A3, results in increased EBV BZLF1 expression (14). Knockdown of EGR1 reduces spontaneous expression of BZLF1 and BRLF1 (24). Since EGR1 expression is enhanced by Zebra, there may be a positive feedback loop stimulating EGR1 action on the BZLF1 and BRLF1 promoters. The BZLF1 promoter (Zp) is also stimulated by overexpression of FOS/JUN, an effect that is enhanced by treatment with transforming growth factor-β (TGF-β) and overexpression of Smad3/Smad4 (25). Stimulation of Zp was independent of Zebra protein, since Zp reporter activation by FOS/JUN occurred in both EBV-positive and EBV-negative cell lines.

The mechanisms by which VPM and VPA block EBV lytic reactivation may involve altering expression of one or more cellular immediate-early genes that influence expression of the EBV transactivator genes. VPM did not enhance the expression of EGR1 or FOS. In fact, VPM blocked upregulation of EGR1 and FOS by butyrate (Fig. 7). It is plausible that blockade of expression of cellular IE genes contributes to mechanisms by which VPM inhibits the expression of EBV transactivator genes. However, VPA stimulates the expression of EGR1 and FOS; therefore, the mechanisms by which VPM and VPA regulate cellular gene expression differ. If there are common ways in which VPA and VPM block EBV lytic reactivation via regulation of cellular immediate-early genes, genes other than EGR1 and FOS must play a role.

Potential therapeutic use of VPA and VPM in medicine. Inhibitors of the EBV lytic cycle are candidates for treatment of diseases in which there is a high viral load of EBV associated with increased levels of lytic replication. Currently utilized antiviral drugs target viral DNA replication. Since VPM and VPA target two additional steps in the viral lytic pathway, namely, reactivation from latency and expression of viral late proteins (Fig. 2 and 6), VPA and VPM might prove useful for therapy of diseases with increased lytic replication. Primary EBV infection during adolescence causes infectious mononucleosis, a disease characterized by high levels of lytic replication in the oropharynx and a high viral load in the blood. Oral hairy leukoplasia results from lytic replication of EBV in the tongue (26). The lytic cycle of EBV also plays a critical role in oncogenesis. Increased viral load precedes the onset of nasopharyngeal carcinoma, Burkitt lymphoma, and Hodgkin lymphoma by months to years (27–29). Suppression of the immune system during AIDS or following organ transplantation results in reactivation of EBV, high viral loads, and increased risk of cancer. Since the inhibitory effects of VPA and VPM described here occur in lymphoid cells, drugs of this class may find use in treatment of patients with high viral loads secondary to immunosuppression with a risk of developing lymphoid malignancies.

Reactivation or inhibition of other viruses. An important issue to consider in the use of VPA or VPM in patients with EBV-associated diseases is their potential to reactivate coexisting latent viral infections, particularly with other herpesviruses, which are common and establish a lifelong latent infection. The human herpesvirus most closely related to EBV is KSHV. The lytic cycle of KSHV is induced by VPA (15). However, since VPM does not induce lytic KSHV in primary effusion lymphoma cells (Fig. 8), VPM might be preferable to VPA for treatment of patients coinfected with EBV and KSHV. Among other herpesviruses, pretreatment of cells with VPA results in increased expression of CMV lytic antigens and stimulates CMV replication (30–32). Treatment with VPA increases expression of the CMV IE promoter reporter (33). Our results also show increased expression of Zebra from the CMV IE promoter by VPA, and also by butyrate (Fig. 6). However, the level of expression of Zebra from the plasmid driven by the CMV IE promoter in cells treated with VPM was the same as in untreated cells (Fig. 6). Thus, a potential advantage of the use of VPM is that it does not reactivate KSHV or stimulate the CMV IE promoter. Further work is needed to assess whether VPM has an inhibitory effect on the replication of CMV or other members of the herpesvirus family.

In conclusion, the novel observations reported herein are useful to generate hypotheses for future studies to unravel the mechanistic details of the pathways of EBV lytic reactivation. VPM is likely to specifically impact cellular gene expression or other aspects of cellular physiology that are crucial for viral reactivation. Our discovery that VPM is an inhibitor of at least two steps in EBV lytic reactivation, without causing HDAC inhibition, allows investigation of changes in cellular gene expression or other aspects of cellular physiology that control or modify different temporal stages of the EB viral life cycle. Targeting EBV lytic reactivation with drugs such as VPM may prove to have prophylactic or therapeutic potential for EBV-associated malignancies in which lytic reactivation precedes or accompanies development of the cancer.

MATERIALS AND METHODS

Cell lines. The HH514-16 Burkitt lymphoma cell line is a subclone of the EBV-infected P3HR-1 cell line (34). Raji is a Burkitt lymphoma-derived cell line (35). HH-B2 is a KSHV-infected primary effusion lymphoma cell line (36). Cells were cultured in RPMI 1640 containing 8% fetal bovine serum, penicillin (50 U/ml), streptomycin (50 μg/ml), and amphotericin B (1 μg/ml).

Chemical treatment and transfection of cell lines. Cells were subcultured to 3 × 10⁵ cells/ml 48 h prior to each experiment. Cells at 1 × 10⁵/ml were treated with chemical stimuli for the duration noted in the figure legends. Sodium butyrate (NaB) and sodium valproate (VPA) (Sigma) were prepared as 1 M solutions in water. VPM (Alfa Aesar), TPA (Calbiochem), 4ynVPA (ABS205; Tocris/Santa Cruz Biotechnology), and butyramide and isovaleramide (Sigma) stocks were made in dimethyl sulfoxide. The chemical agents were added at the following concentrations: butyrate (3 mM), VPA or VPM (10 mM), TPA (20 ng/ml). Cell viability was measured by counting cells that excluded staining with trypan blue. In all drug treatment experiments, the cell viability was ≥90%. Cells (5 × 10⁵) were transfected using nucleofection (Lonza) with either 2 μg of an empty vector with a CMV promoter or 2 μg of a plasmid encoding Zebra. In some experiments (Fig. 6), chemical agents were added 1 h after transfection.

Western blot analysis. Cells that were untreated or treated with chemical stimuli were harvested at the times indicated in the figure legends. Total cell extracts were electrophoresed in 12% SDS-polyacrylamide gels (Bio-Rad) and transferred to nitrocellulose membranes. Rabbit polyclonal antibodies were used to detect histone H3 acetylated at lysine 9 and lysine 14 (catalog number 06-599; EMD Millipore) and EBV BRF3. Mouse monoclonal antibodies were used to detect Zebra (BZ1) (37), EA-D, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; ab8245; Abcam), and β-actin (A5316; Sigma). Protein levels were determined by densitometry.

Reverse transcription–quantitative PCR. Total RNA was isolated using an RNasy kit with on-column DNase digestion (Qiagen). Relative transcript levels were determined using gene-specific primers of the iScript SYBR green reverse transcription–quantitative PCR (RT-qPCR) kit (Bio-Rad). Primers for the EBV and cellular mRNAs studied have been described previously (6, 7). Relative expression levels were calculated us-
or the decision to submit the work for publication.

FUNDING INFORMATION
This work, including the efforts of George Miller, was funded by HHS | NIH | National Cancer Institute (NCI) (CA12055 and CA16038 to G.M. and F32CA165705 to K.L.G.).

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES
1. Luka J, Kallin B, Klein G. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228–231. http://dx.doi.org/10.1016/0042-6822(79)90455-0.

2. Gorres KL, Daigle D, Mohanram S, Miller G. 2014. Activation and repression of Epstein-Barr virus and Kaposis’s sarcoma-associated herpesvirus lytic virus cycles by short- and medium-chain fatty acids. J Virol 88:8028–8044. http://dx.doi.org/10.1128/JVI.01072-14.

3. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. 1990. Autoregulation of Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through co-transaction factor activates expression of the Epstein-Barr virus immediate-early growth response 1 gene. J Virol 64:1079–1086. http://dx.doi.org/10.1128/0014-2999.90.5.4727-0.

4. Countryman JK, Gradoville L, Miller G. 2008. Histone hyperacetylation occurs on promoters of lytic regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J Virol 82:4706–4719. http://dx.doi.org/10.1128/JVI.00116-08.

5. Daigle D, Megvola C, El-Guindy A, Gradoville L, Tuck D, Miller G, Bhaduri McIntosh S, Countryman JK, Gradoville L, Miller G. 2009. Novel histone deacetylase inhibitor activates the Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol 84:993–1004. http://dx.doi.org/10.1128/JVI.00722-09.

6. Ye J, Gradoville L, Daigle D, Miller G. 2007. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kapo- si’s sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists. J Virol 81:9279–9291. http://dx.doi.org/10.1128/JVI.00982-07.

7. Daigle D, Gradoville L, Tuck D, Schulz V, Wang’ondu R, Ye J, Gorres K, Miller G. 2011. Valproic acid antagonizes the capacity of other HDAC inhibitors to activate the Epstein-Barr virus lytic cycle. J Virol 85:5628–5643. http://dx.doi.org/10.1128/JVI.02659-10.

8. Eydel S, Yagen B, Shimshoni J, Bieler M. 2005. Histone deacetylase inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem Pharmacol 69:1501–1508. http://dx.doi.org/10.1016/j.bcp.2005.02.012.

9. Gööttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pellicci PG, Heinzel T. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978. http://dx.doi.org/10.1093/emboj/20.24.6969.

10. Fleming E, Speck SH. 1990. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol 64:1227–1322.

11. Lin P, Liu S, Speck SH. 1998. Identification of a negative cis element within the ZIIZ domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. J Virol 72:8230–8239.

12. Yu X, Wang Z, Mertz JE. 2007. ZEB1 regulates the latent-lytic switch in Epstein-Barr virus. PLoS Pathog 3:e194. http://dx.doi.org/10.1371/journal.ppat.0000319.

13. De Poorter JJ, Lipinski KS, Neelissen RG, Huizinga TW, Hooeben RC. 2006. Optimization of short-term transient transgene expression by sodium butyrate and ubiquitous chromatin opening elements (UCOEs). J Gene Med 9:639–648. http://dx.doi.org/10.1002/jgme.1057.

14. Ye J, Gradoville L, Miller G. 2010. Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bZlf1 and bRf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line. J Virol 84:12405–12418. http://dx.doi.org/10.1128/JVI.01510-10.

15. Shaw RN, Arbiser JL, Offermann MK. 2000. Valproic acid induces human herpesvirus 8 lytic gene expression in BCBl-1 cells. AIDS 14:899–902. http://dx.doi.org/10.1016/0008-5472(98)00462-2.

16. Hauck RS, Nau H, Elmazar MMA. 1991. On the development of alternative antiepileptic drugs. Lack of enantioselectivity of the anticonvulsant activity, in contrast to teratogenicity, of 2-n-propyl-4-pentynoic acid and 2-n-propyl-4-pentynoic acid, analogues of the anticonvulsant valproic acid. Naturwissenschaften 78:272–274. http://dx.doi.org/10.1007/BF01134356.

17. Nau H, Hauck RS, Ehlers K. 1991. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 69:310–321. http://dx.doi.org/10.1111/j.1600-0773.1991.tb01303.x.

18. Eikel D, Lampen A, Nau H. 2006. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from qualitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 19:272–278. http://dx.doi.org/10.1021/tr0502241.

19. Bojic U, El-Fahmy H, Evers AI, O’Driscoll E, O’Connell C, Berezin V, Kawa A, Lepekhin E, Boek E, Regan CM, Nau H. 1998. Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interaction at a hydrophobic centre. Eur J Pharmacol 354:289–299. http://dx.doi.org/10.1016/S0014-2999(98)00046-2.

20. Nau H, Loscher W. 1986. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam Appl Toxicol 6:669–676. http://dx.doi.org/10.1016/0162-2405(86)90180-6.

21. Phiel CJ, Zhang F, Huang EY, Guenthner MG, Lazar MA, Klein PS. 2001. Histone deacetylation is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734–36741. http://dx.doi.org/10.1074/jbc.M101272200.

22. Monti B, Polazzi E, Contestabile A. 2009. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2:95–109. http://dx.doi.org/10.2174/1874467210902010099.

23. Zalani S, Helly-Guthrie E, Kenney S. 1995. The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. J Virol 69:3816–3823.

24. Chen Y, Liu HH, Chen Y, Lu CY, Chen SW, Takada K, Tsai CH. 2006. Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. J Virol 80:7748–7755. http://dx.doi.org/10.1128/JVI.02608-05.

25. Liang CL, Chen JL, Huo YP, Ou JT, Chang YS. 2002. Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through co-ordinativity of Smads and c-Jun/c-Fos proteins. J Biol Chem 277:23345–23357. http://dx.doi.org/10.1074/jbc.M107420200.

26. Greenspan JS, Greenspan D, Lennette ET, Abrams DI, Conant MA, Petersen V, Freese UK. 1985. Replication of Epstein-Barr virus within the epithelial-cells of oral hairy leukoplakia, an AIDS-associated lesion. N Engl J Med 313:1564–1571. http://dx.doi.org/10.1056/NEJM198512193132302.

27. Mueller N, Mohar A, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J. 1991. Epstein-Barr virus
antibody patterns preceding the diagnosis of non-Hodgkin’s lymphoma. Int J Cancer 49:387–393. http://dx.doi.org/10.1002/ijc.2910490313.

28. De-Thé G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W. 1978. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature 274:756–761. http://dx.doi.org/10.1038/274756a0.

29. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z, Meng NN. 1985. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 36:545–547. http://dx.doi.org/10.1002/ijc.2910360505.

30. Michaelis M, Suhan T, Reinisch A, Reisenauer A, Fleckenstein C, Eikel D, Gumbel H, Doerr HW, Nau H, Cinatl J, Jr. 2005. Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition. Invest Ophthalmol Vis Sci 46:3451–3457. http://dx.doi.org/10.1167/iovs.05-0360.

31. Michaelis M, Kohler N, Reinisch A, Eikel D, Gravemann U, Doerr HW, Nau H, Cinatl J, Jr. 2004. Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid. Biochem Pharmacol 68:531–538. http://dx.doi.org/10.1016/j.bcp.2004.04.013.

32. Michaelis M, Ha TA, Doerr HW, Cinatl J, Jr. 2008. Valproic acid interferes with antiviral treatment in human cytomegalovirus-infected endothelial cells. Cardiovasc Res 77:544–550. http://dx.doi.org/10.1093/cvr/cvm061.

33. Kuntz-Simon G, Obert G. 1995. Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication. J Gen Virol 76:1409–1415. http://dx.doi.org/10.1099/0022-1317-76-6-1409.

34. Heston L, Rabson M, Brown N, Miller G. 1982. New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature 295:160–163. http://dx.doi.org/10.1038/295160a0.

35. Epstein MA, Aching BG, Barr YM, Zajac B, Henle G, Henle W. 1966. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 37:547–559.

36. Gradoville L, Gerlach J, Grogan E, Shedd D, Nikiforow S, Metroka C, Miller G. 2000. Kaposi’s sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH B2 primary effusion lymphoma cell line. J Virol 74:6207–6212. http://dx.doi.org/10.1128/JVI.74.13.6207-6212.2000.

37. Young LS, Lau R, Rowe M, Niedobitek G, Packham G, Shanahan F, Rowe DT, Greenspan D, Greenspan JS, Rickinson AB, Farrell PJ. 1991. Differentiation-associated expression of the Epstein-Barr-virus BZLF1 transactivator protein in oral hairy leukoplaikia. J Virol 65:2868–2874.